Back to Search
WILLIAM SYMMANS, M.D.
M.D.
Cytopathology Physician
NPI: 1669577367IndividualAccepts Medicare
Specialties, Licenses & Credentials
Cytopathology PhysicianPrimary
Pathology — Cytopathology
Code: 207ZC0500X
K9913(TX)
Education
OTHER
Class of 1987
Research & Publications (20)
Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy.
PMID 18436523·Ann Oncol·2008
8-other
A pathologist's perspective on emerging genomic tests for breast cancer.
PMID 17512433·Semin Oncol·2007
6-review
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
PMID 17785706·J Clin Oncol·2007
8-other
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding.
PMID 16322343·Endocr Relat Cancer·2005
4-observational
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma.
PMID 12784330·Cancer·2003
4-observational
Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines.
PMID 19603265·Breast Cancer Res Treat·2010
8-other
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.
PMID 19596702·Ann Oncol·2009
8-other
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.
PMID 19147748·Clin Cancer Res·2009
8-other
Genomic grade index is associated with response to chemotherapy in patients with breast cancer.
PMID 19364972·J Clin Oncol·2009
8-other
Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.
PMID 19667268·J Clin Oncol·2009
8-other
Ductal carcinoma in situ: state of the science and roadmap to advance the field.
PMID 19064970·J Clin Oncol·2009
6-review
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
PMID 19346299·Oncologist·2009
6-review
Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations.
PMID 19289584·Am J Clin Pathol·2009
4-observational
Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria.
PMID 19605817·Am J Clin Pathol·2009
4-observational
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.
PMID 19047121·Clin Cancer Res·2008
3-trial
Commercialized multigene predictors of clinical outcome for breast cancer.
PMID 18515733·Oncologist·2008
4-observational
Evaluation of biological pathways involved in chemotherapy response in breast cancer.
PMID 18445275·Breast Cancer Res·2008
8-other
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
PMID 18667396·Ann Oncol·2008
4-observational
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
PMID 18676830·Cancer Res·2008
8-other
Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer.
PMID 18662965·J Clin Oncol·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD, 77030-4009
HOUSTON, TX 77030 - Phone
- (713) 792-6161
Quick Facts
- NPI
- 1669577367
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 39
- Publications
- 20
Are you this provider?
Claim Your Profile